课题基金 / 基金详情

Benzodiazepine-related harms in young people: Informing policy, interventions, and prescribing

Benzodiazepine-related harms in young people: Informing policy, interventions, and prescribing
年轻人中与苯二氮卓相关的危害:为政策、干预措施和处方提供信息
批准号:
10565898
负责人:
Greta Bushnell
金额:
$19.61万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-15 至 2026-02-28

项目摘要

项目成果

Greta Bushnell的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要。 这项指导研究科学家发展奖(K01)的建议将发展Greta Bushnell博士的职业生涯 作为一名独立调查员,并使她能够进入专注于评估的新研究领域 与滥用和滥用有关的青少年处方药发病率及政策和做法 可以减轻这些有害后果。这一新的研究方向需要在药物滥用方面进行独特的培训 政策,滥用和滥用处方药的责任,青少年药物使用的发展,分析 州级政策,以及解决混乱控制的先进方法。支持培训计划 布什内尔博士将由一支经验丰富的研究团队完成这项拟议的研究,填补关键空白 周围苯二氮(BZD)滥用和滥用对年轻人的危害及可改变的因素 减少这些危害。这项研究的重点是在与BZD相关的发病率上升的适当时间,继续说 处方,缺乏药物使用问题的发育风险青年的安全数据,以及目前 利用阿片类药物相关政策减少BZD相关危害的机会。与BZD有关的过量死亡 近年来大幅增加,2017年有11,500人死亡,部分原因是阿片类药物危机,以及 年,青少年和年轻人因BZD相关中毒而急诊39,000人次。 2016年。尽管BZD经常被开给青少年(3%)和年轻人(6%),但没有 BZD治疗后过量用药风险的估计以及BZD是否和程度尚不清楚 给年轻人开处方会无意中增加BZD或其他物质在以后生活中滥用的风险。处方药 监测计划(PDMP)代表着一种潜在的重要但未被研究的手段,以缓解BZD- 相关发病率。PDMP是国家运营的监控系统,收集患者关于处方的详细信息 有能力检测危险处方的受控物质。布什内尔博士将使用大型、国家级 行政索赔数据(2000-2018),涵盖私人和公共保险的年轻人(10-29岁)至 评估选定的州PDMP功能是否减少了BZD相关的危害和年轻人服用BZD的风险 人员(目标1)。为了评估个人水平的风险,她将量化BZD治疗后的过量风险 使用国家声明将年轻人与替代疗法和处方细节(目标2)进行比较 具有来自区域卫生资源文件的测量的数据集。然后她将评估青少年BZD是否 治疗会增加成年初期滥用BZD或使用有害物质的下游风险(目标3) 成年初期全国高三学生未来监测抽样调查 (»2450/年,1976-2016)。该提案将向R01提交的关于确定青年特有的风险因素的意见提供信息 从使用BZDS或其他受控物质治疗到滥用和利用这一点 为干预措施提供信息的知识。解决这些问题和发展这一新的研究路线只是 K01可以提供高强度的培训、支持和保护时间。
英文摘要
PROJECT SUMMARY/ABSTRACT. This Mentored Research Scientist Development Award (K01) proposal will develop Dr. Greta Bushnell’s career as an independent investigator, and enable her to advance into a new line of research focused on evaluating misuse and abuse related morbidity of medicines prescribed to young people and the policies and practices that can mitigate these harmful outcomes. This new direction of research requires distinct training in substance abuse policy, misuse and abuse liability of prescription drugs, adolescent development of substance use, analysis of state-level policies, and advanced methods to address confounding control. With a training program supported by an experienced team of investigators, Dr. Bushnell will complete the proposed research, filling key gaps surrounding benzodiazepine (BZD) misuse and abuse related harms in young people and modifiable factors to reduce these harms. This research focus comes at a pertinent time of rising BZD-related morbidity, continued prescribing, lack of safety data in youth at developmental risk for substance use problems, and current opportunities to leverage opioid-related policies to reduce BZD-related harms. Overdose deaths involving BZDs significantly increased in recent years with »11,500 deaths in 2017, partially attributed to the opioid crisis, and in adolescents and young adults there were »39,000 emergency department visits for BZD-related poisonings in 2016. Despite BZDs being frequently prescribed to adolescents (3%) and young adults (6%), there are no estimates on overdose risk following BZD treatment and it is unknown whether and to what extent BZD prescribing to youth inadvertently increases risk of BZD or other substance misuse later in life. Prescription drug monitoring programs (PDMPs) represent a potentially important, but understudied, means to mitigate BZD- related morbidity. PDMPs are state-run surveillance systems collecting patient details on prescriptions for controlled substances with capabilities to detect risky prescribing. Dr. Bushnell will use large, national administrative claims data (2000-2018) covering privately and publicly insured young people (10-29 years) to evaluate whether selected state PDMP features decrease BZD-related harms and risky BZD prescribing in young people (Aim 1). To evaluate individual-level risks, she will quantify overdose risk following BZD treatment in young people compared to alternative treatments and by prescription details (Aim 2) using the national claims datasets with measures from Area Health Resources Files. She will then evaluate whether adolescent BZD treatment increases downstream risks of BZD misuse or harmful substance use in early adulthood (Aim 3) using the nationwide Monitoring the Future sample of high school seniors with panel surveys into early adulthood (»2,450/year, 1976-2016). The proposal will inform an R01 submission on identifying youth-specific risk factors in the progression from treatment with BZDs, or other controlled substances, to abuse and leveraging this knowledge to inform interventions. Addressing these questions and developing this new line of research are only feasible with intensive training, support, and protected time, which the K01 can provide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Benzodiazepine-related harms in young people: Informing policy, interventions, and prescribing
Pediatric anxiety: Pharmacotherapy and psychotherapy utilization and serious adverse outcomes
海外基金